Children with heterozygous familial hypercholesterolaemia (FH) should be managed by paediatric health professionals with expertise in FH.• Statin to be considered by the age of 10 years and use age appropriate target LDL-C level in children with FH.• Dietary and life style advice should begin in early childhood.• From the age of 14 years, consider joint review with adult lipidologist in transition clinic with transfer to adult lipid clinic at 16 to 18 years.
Heterozygous familial hypercholesterolaemia is a common genetic condition characterised by the impaired clearance of low density lipoprotein cholesterol from the bloodstream. Incidence rates can be as high as 1/250 and those confirmed with familial hypercholesterolaemia are predisposed to progressive atherosclerosis throughout childhood, increasing their risk of premature cardiovascular disease. Early identification and initiation of risk factor management and lipid-lowering therapy are fundamental if this risk and its associated comorbidities are to be reduced and a life expectancy similar to that of the general population restored. This article discusses several aspects of familial hypercholesterolaemia including identification, diagnosis through genetic testing and treatment protocols in a tertiary cardiac centre. It aims to share key learning points with other institutions either already established in the care of paediatric patients with familial hypercholesterolaemia or those contemplating forming a service to meet the needs of this growing cohort.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.